[nhstanley]

This isn't the first antibody therapy that tries to reduce plaques (Bapineuzumab, solanezumab, gantenerumab, crenezumab, etc.), but is it the first one to "work" correctly, but still fail? I don't believe so. I think bapineuzumab also showed early promise at reducing plaques, though I don't remember if they did a cognitive analysis that Biogen did here.

Don't get me wrong. I think this is the most promising one we've had, if for no other reason than the method used to develop it. They took people who lived into old age without Alzheimer's, and found antibodies from them that targeted Abeta (so they claim). Really cool stuff, if true, and very promising.